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Amyloidogenic protein aggregation impairs cell function and is a hallmark of
many chronic degenerative disorders. Protein aggregation is also a major event
during acute injury; however, unlike amyloidogenesis, the process of injury-
induced protein aggregation remains largely undefined. To provide this
insight, we profiled the insoluble proteome of several cell types after acute
injury. These experiments show that the disulfide-driven process of nucleo-
cytoplasmic coagulation (NCC) is the main form of injury-induced protein
aggregation. NCC is mechanistically distinct from amyloidogenesis, but still
broadly impairs cell function by promoting the aggregation of hundreds of
abundant and essential intracellular proteins. A small proportion of the intra-
cellular proteome resists NCC and is instead released from necrotic cells.
Notably, the physicochemical properties ofNCC-resistant proteins are contrary
to those of NCC-sensitive proteins. These observations challenge the dogma
that liberation of constituents during necrosis is anarchic. Rather, inherent
physicochemical features including cysteine content, hydrophobicity and
intrinsic disorder determine whether a protein is released from necrotic cells.
Furthermore, as half of the identified NCC-resistant proteins are known auto-
antigens, we propose that physicochemical properties that control NCC also
affect immune tolerance and other host responses important for the restoration
of homeostasis after necrotic injury.1. Introduction
Proteinsmust fold into their native conformation to be fully functional.However, as
the native conformation is labile, all proteins are also capable ofmisfolding. Protein
misfolding exposes hydrophobic regions that form intra- and inter-molecular
associations, which if left unchecked canmultimerize into higher-order toxic aggre-
gates [1]. Protein quality controlmechanisms adequately deal withmost forms and
degrees ofmisfolding.Nonetheless, destabilizingmutations, extremeenvironments
or ageing can overwhelm proteostasis leading to the unwanted accumulation
of aggregatedproteins. Proteinaggregation, and inparticular amyloidogenic aggre-
gation, underlies many chronic age-related diseases including Alzheimer’s disease
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protein aggregation is widely thought to elicit injury.
Paradoxically, protein aggregation is also a key response to
acute tissue injury. Injury-induced protein aggregation was
first described in the 1980s [2–5], where aberrant actin aggrega-
tion occurred in cells after ATP depletion or oxidant exposure.
Subsequent studies showed that actin, myosin, vinculin and
HSP70 all aggregated upon ATP depletion [6–9]. Glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) is another
intracellular protein that readily aggregates during stress in
vitro [10–14] and in vivo [10,14–16]. Injury-induced protein
aggregation has also been observed during hypoxia [17–19].
Recently, we [10,12,20,21] and others [22] have characterized
the process of injury-induced protein aggregation. In particular,
we found that injury can trigger a specific form of protein
aggregation called nucleocytoplasmic coagulation (NCC) [10].
By definition, NCC is a temporally coordinated disulfide-
crosslinking reaction that occurs during late-stage cell death.
NCC causes many intracellular proteins, including actin, tubu-
lin, GAPDH and HSP90b, to convert from a soluble form into
high-molecular-weight insoluble species [10]. In vitro and in
vivo data show that NCC-aggregated proteins promote acti-
vation of the extracellular protease plasmin on the surface of
dead cells [10,20,21]. Surface-bound plasmin then initiates two
forms of clearance: direct proteolytic degradation of dead cells
[10,20] and signalling nearby dendritic cells to increase their
phagocytic capacity [21]. Thus, NCC-aggregated proteins can
be considered a novel ‘damage-associated molecular pattern’
that initiates humoral and cellular responses to sterile injury [23].
Despite these recent advancements the mechanisms of
injury-induced protein aggregation are poorly understood.
Accordingly, to ascertain the basis of injury-induced protein
aggregation, we have used quantitative mass spectrometry to
profile the insoluble proteome of three cell types across different
injury conditions.We find that NCC is a specific consequence of
necrosis. Moreover, our data suggest that NCC is the predomi-
nant formof injury-induced protein aggregation,which affects a
much wider array of proteins than first thought. Surprisingly, a
small subset of proteins avoids NCC-mediated aggregation.
Comparison of NCC-resistant and NCC-sensitive proteins
uncovers two fundamental principles: (i) that injury-induced
aggregation is distinguishable fromamyloidogenic aggregation,
and (ii) that a protein’s inherent physicochemical properties
determines whether it is retained or released from necrotic cells.
Altogether, NCC represents a ‘fail-safe switch’ that broadly
incapacitates cellular functions during necrosis and selectively
retains debris at the site of injury. As a result, we propose that
NCC is a beneficial event that pacifies the reactivity of necrotic
cells. In support of this notion, and consistent with the fact that
defective removal of dead cells is a strong risk factor for auto-
immune disease [24–30], we note that many proteins which
evade NCC are also recognized autoantigens. Future studies
should now assess whether mutations that alter a protein’s pro-
pensity to undergoNCC can in turn influence its ability to act as
an autoantigen.2. Results and discussion
2.1. Profiling the insoluble proteome of injured cells
We first characterized injury and protein aggregation in
human Jurkat lymphocyte cells treated with etoposide (atopoisomerase-II inhibitor), staurosporine (a pan-kinase inhibi-
tor) or Fas ligand (FasL; a TNF death receptor agonist). All
agonists induced apoptosis in Jurkat cells (indicated by an
increase in phosphatidylserine exposure and caspase-mediated
RIPK1 cleavage; figure 1a; electronic supplementary material,
figure S1a,b). More specifically, FasL and staurosporine
triggered a similar degree/rate of injury, with early stage
apoptosis evident within 3 h of treatment (indicated by
phosphatidylserine-positive, TO-PRO-3-negative staining; elec-
tronic supplementary material, figure S1a) and transition to a
secondary necrotic state within 24 h of treatment (indicated by
complete loss ofmetabolism,plasmamembranedisruption, pro-
nounced LDH release and the acquirement of TO-PRO-3-
positive staining; figure 1a; electronic supplementary material,
figure S1a). Note that neither necroptosis (mediated by full-
lengthRIPK1) norautophagic death (mediated by LC3 cleavage;
electronic supplementary material, figure S1b) was evident after
FasL or staurosporine treatment. By contrast, etoposide caused
early stage apoptosis after 24 h of treatmentwith no signs of sec-
ondary necrosis (as indicated by LDH retention, plasma
membrane impermeability, partial metabolic suppression, and
modest elevations in phosphatidylserine exposure and RIPK1
cleavage; figure 1a; electronic supplementary material, figure
S1a). Lastly, we confirmed protein aggregation in Jurkat cells
during the later stages of staurosporine-treatment with synchro-
nous conversion of HSP90b, a/b-tubulin and b-actin from a
soluble state into insoluble high molecular weight disulfide-
crosslinked species (electronic supplementary material, figure
S1c). Disulfide-crosslinked insoluble forms of these same pro-
teins were also observed after FasL treatment, but not after
etoposide treatment (not shown). Note that the coordinated
loss of protein solubility upon secondary necrosis represents a
genuine aggregation event (rather than merely being a conse-
quence of disulfide crosslinking), as these same insoluble
proteins were observed in the presence of a reducing agent
(electronic supplementary material, figure S1d). Thus, injury-
induced protein aggregation in Jurkat cells occurred specifically
during necrosis, but not during early stage apoptosis. Moreover,
as the vast majority of insoluble material was disulfide-
crosslinked (electronic supplementary material, figure S1c),
NCC appears to be the predominant form of injury-induced
protein aggregation.
Next, we profiled the insoluble proteome of Jurkat cells after
24 h of treatment with vehicle, etoposide, staurosporine or FasL
using the quantitative mass spectrometry-based technique
of SILAC (stable isotope labelling by amino acids in cell culture
[32]; see electronic supplementary material, figure S2
and Material and methods for experimental details). This
approach allowed the identification of hundreds to thousands
of insoluble proteins per experiment with measurement of
their relative abundance between uninjured and injured cells.
Figure 1b and electronic supplementary material, table S1
summarize the SILAC results. Proteins with an increased
right-shifted SILAC ratio in figure 1b were assumed to have
undergone injury-induced aggregation, as this shift was only
observed in staurosporine- or FasL-treated Jurkat cells. To
verify this assumption, 12 proteins identified as putative aggre-
gators in the SILAC experiments were subjected to immunoblot
analysis. As shown in figure 2a, all 12 proteins were confirmed
to undergo injury-induced protein aggregation in necrotic
Jurkat cells. Consistent with the initial description of NCC
in neuronal cells [10], necrosis in Jurkat cells caused all tested
proteins to convert into insoluble high-molecular-weight
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Figure 1. Diametric changes in the abundance of insoluble intracellular proteins upon secondary necrosis. (a) Jurkat lymphocytes were treated with vehicle
(uninjured) or injured with etoposide, staurosporine or Fas ligand. Phosphatidylserine (PS) exposure (relative AnnexinV-signal geomean), metabolism (% MTS)
and necrosis (% LDH and % trypan blue positive) were measured after 24 h of treatment. Data are presented as mean þ s.e.m. from n ¼ 3–7 independent
experiments. *p , 0.05, **p, 0.01 and ****p , 0.0001 relative to uninjured cultures as determined by one-way ANOVA with Newman–Keuls correction.
By definition, apoptosis is an energetic process, whereas necrosis coincides with metabolic incompetency. Therefore, because 24 h incubation with staurosporine
or Fas ligand abolished metabolism (in conjunction with high levels of LDH release, trypan blue uptake and TO-PRO-3-staining; electronic supplementary material,
figure S1a), we have concluded that these agonists produced a secondary necrotic state by this time point. (b) Jurkat cultures were labelled with either heavy or
light lysine isotopes and treated with vehicle (uninjured), etoposide, staurosporine or Fas ligand for 24 h. Triton-insoluble fractions were extracted and proteins
identified using quantitative mass spectrometry. The abundance of identified proteins relative to that in isotopically different uninjured cultures was then plotted
as the log2 ratio of the stable isotope label (SILAC); where an increased ratio indicates more of a specific insoluble protein in injured cells relative to uninjured cells
and a decreased ratio indicates less of a specific insoluble protein in injured cells relative to uninjured cells. Proteins with a log2 ratio. þ0.6 were gated into the
NCC-participating subproteome (green colour) and proteins with a log2 ratio, 20.6 were gated into the NCC-resistant subproteome (pink colour). This gating was
also chosen based on the recommendations of Zhang & Neubert [31]. Inserts show the percentage of identified proteins that fall within each gate. (c) Partial overlap
in the gated subproteomes between staurosporine- and Fas ligand-induced necrotic Jurkat cells. The number of proteins within each gate is shown. (d ) Partial
overlap in the NCC-participating subproteome between staurosporine-induced necrotic Jurkat cells versus staurosporine-induced necrotic human U937 monocytes.
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figure 2b) and to relocate into distinct aberrant subcellular struc-
tures (as assessed by super-resolution microscopy; figure 2c)
which stained strongly for the presence of oxidized thiols (as
assessed by confocal microscopy; figure 2d). Thus, we con-
cluded that proteins that exhibited log2 SILAC ratios greater
than þ0.6 were indeed ‘NCC-participating’ proteins (green
colour in figure 1b). Moreover, as 30–46% of the identified
proteins underwent NCC in necrotic Jurkat cells (figure 1b),
injury-induced aggregation appears to affect a much larger
portion of the proteome than prior studies suggest.
Closer inspection of the SILAC data revealed another
population of proteins with log2 SILAC ratios less than 20.6
(11–13% of identified targets; red colour in figure 1b). These
‘NCC-resistant’ proteins were decreased in abundance in theinsoluble fraction of necrotic Jurkat cells relative to uninjured
cells, suggesting that they were either degraded or avoided
aggregation during injury. To assess which scenario was appli-
cable, six putative NCC-resistant proteins were selected for
immunoblot analysis. Consistent with the SILAC data, all six
tested proteins were decreased in abundance in the insoluble
fraction of necrotic Jurkat cells relative to uninjured cells
(figure 3a). Notably, the disappearance of these NCC-resistant
proteins in necrotic cells did not result in the commensurate
appearance of lowermolecularweight immunoreactive species,
suggesting that they were not being degraded (figure 3a). Next,
we reasoned that if a protein avoided both NCC and degra-
dation, then it should instead be released into the extracellular
milieu upon necrosis. Consequently, we assayed for the pres-
ence of FUS (also called ‘RNA-binding protein FUS’ or
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Figure 2. NCC is the main form of injury-induced protein aggregation. (a–d ) Jurkat cells were treated with vehicle (uninjured), etoposide, staurosporine or Fas ligand for
24 h. (a) Triton-soluble and -insoluble proteins were isolated and subjected to SDS-PAGE under reducing conditions followed by immunoblot analysis. Results are repre-
sentative of n ¼ 3–6 independent experiments. (b) Triton-soluble and -insoluble proteins were isolated and subjected to SDS-PAGE in the presence/absence of
dithiothreitol (DTT) followed by immunoblot analysis. Results are representative of n ¼ 2–3 independent experiments. (c) Cells were fixed, subjected to immunofluor-
escence and imaged by super-resolution microscopy with xy-resolution of 70 nm. Shown are representative x,y micrographs, where the bottom two rows are magnified
micrographs taken from the boxed areas in the top two rows. Staurosporine-induced necrosis causes NCC-proteins (a-tubulin, EF2 and MCM7) to relocate into aberrant and
distinct structures. Arrows indicate EF2 deposits that exhibit little-to-no staining for tubulin or MCM7. Arrowheads indicate MCM7 deposits that exhibit little-to-no staining for
tubulin or EF2. Note, the procedure used to stain oxidized thiols was not compatible with the sample preparation for super-resolution microscopy. (d ) Cells were fixed and
subjected to immunofluorescence with maleimide co-staining for oxidized thiols. Shown are representative x,y confocal micrographs. Staurosporine-induced necrosis leads to
nuclear breakdown and a marked increase in oxidized thiols that colocalize with aberrantly deposited NCC-proteins (3PDGH, GAPDH, MCM7, EF1, EF2 and a-tubulin).
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detected NCC-resistant protein) in the conditioned media
from injured Jurkat cells. As shown in figure 3b, full-length
FUS, but not MCM7 (an NCC-participating protein), was
readily detected in the conditioned media of necrotic Jurkat
cells. To the best of our knowledge, this is the first report that
the ubiquitous protein, FUS, is released from necrotic cells. It
remains to bedeterminedwhether otherNCC-resistant proteins
are released from necrotic cells, but this seems highly likely (for
reasons provided below with figures 4 and 5). The capacity of
FUS and other NCC-resistant proteins to act as paracrine com-
municators of injury should now be assessed, especially given
the influence of NCC on the proteolytic [10,20] and phagocytic
[21] removal of dead cells. It will also be interesting to see if FUS
released from necrotic cells has a role during FUS-mediated
amyotrophic lateral sclerosis [37].
We next examined injury-induced protein aggregation in
human U937 monocyte cells, where both secondary necrosis
(electronic supplementary material, figure S3a) and NCC(electronic supplementary material, figure S3b) occurred after
24 h of treatment with either etoposide or staurosporine.
SILACexperiments showed that similar, albeitmorepronounced
changes to the insoluble proteome occurred upon secondary
necrosis in U937 cells (figure 1d; electronic supplementary
material, figure S3c), with 53–61% of proteins participating in
NCC and 16–30% of proteins avoiding NCC (electronic supple-
mentary material, figure S3c). The reason for this increased
aggregation of the U937 proteome is unknown, but may reflect
the heightened sensitivity of U937 cells to injury (cf. figure 1a
and electronic supplementary material, figure S3a), or could
relate to the extreme differences in the metabolism of monocytes
and lymphocytes [38]. It is telling that etoposide elicited neither
necrosis nor NCC in Jurkat cells, but strongly induced both sec-
ondary necrosis and NCC in U937 cells. This observation
emphasizes that necrosis per se is the major cellular correlate of
NCC. It is also salient that, despite marked differences in the
means by which etoposide, staurosporine and FasL injure cells,
many of the same proteins underwent NCC when these
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Figure 3. A subset of intracellular proteins avoids NCC and is released into the extracellular milieu upon necrosis. (a,b) Jurkat cells were treated with vehicle
(uninjured), etoposide, staurosporine or Fas ligand for 24 h. (a) Triton-soluble and -insoluble proteins were isolated and subjected to SDS-PAGE under reducing
conditions followed by immunoblot analysis. Results are representative of n ¼ 3–5 independent experiments. (b) Conditioned media were collected and the
amount of MCM7 (an NCC-participating protein) and FUS (an NCC-resistant protein) assayed via immunoprecipitation and subsequent immunoblotting (simul-
taneously using primary antibodies for both MCM7 and FUS). The approximately 50 kDa immunoreactive species represents the long-chain immunoglobulin
used for the immunoprecipitation. The approximately 70 kDa immunoreactive species represents full-length FUS. No MCM7 (an approx. 100 kDa protein) was
detected in the conditioned media. The graph depicts the collated quantitation of the immunoprecipitated FUS signal normalized to the total amount of soluble
full-length FUS in uninjured cells. Data are presented as mean þ s.e.m. from n ¼ 4 independent experiments. **p, 0.01 and ***p, 0.001 as determined by
one-way ANOVA with Newman–Keuls correction.
rsob.royalsocietypublishing.org
Open
Biol.6:160098
5
 on November 23, 2017http://rsob.royalsocietypublishing.org/Downloaded from treatments caused necrosis (figure 1c; electronic supplementary
material, figure S3d). Such significant overlap in the insoluble
proteome across different cell types and necrotic conditions
denotes that a common underlyingmechanism governs the par-
ticipation/resistance of proteins to NCC.2.2. Elucidating the physicochemical basis of
nucleocytoplasmic coagulation
All proteins are capable of aggregating; however, the propen-
sity, kinetics and conformations of aggregation are largely
determined by the inherent physicochemical properties of the
protein in question. Therefore, a high-confidence list of NCC-
participating, NCC-resistant and intermediary ‘unchanged’
proteins was collated from the Jurkat and U937 SILAC datasets
(electronic supplementary material, table S1), and their primary
sequences were compared to ascertain the physicochemical
basis ofNCC. Themost prominent feature ofNCC-participating
proteins was their relatively high cysteine content (figure 4a),
with a significant correlation between cysteine content and the
degree of injury-induced aggregation (figure 4b). This finding,
in conjunction with our earlier publications showing that
NCC-aggregates are disulfide-crosslinked [10,12], highlights
the importance of cysteine residues to NCC. Conversely,
NCC-resistant proteins were found to be devoid of native disul-
fide bonds (figure 4c), implying that unlike NCC-participating
proteins, the functions/folding of NCC-resistant proteins may
be independent of cysteine reactivity. With the exception of C,
D, N andH residues, the amino acid content ofNCC-participat-
ing proteins aligned well with that of amyloidogenic peptides,
as defined in [33,39,40] (figure 4a and not shown). This obser-
vation suggests that amyloidogenic aggregation and NCC aresimilar, but nevertheless distinct processes. We propose that
NCC is an ‘off-shoot’ of amyloidogenic aggregation (electronic
supplementary material, figure S4). NCC and amyloidogenesis
may even be at cross-purposes, given that amyloidogenesis
involves the slow organized association of discrete protein seg-
ments in the absence of disulfide crosslinking, whereas NCC
involves rapid multivalent associations in the presence of
disulfide crosslinking (electronic supplementary material,
figure S4). Further evidence for this hypothesis stems from
our priorwork showing thatNCC-aggregates exhibit a prefibril-
lar oligomeric conformation with no subsequent appearance of
fibrillar species [10].
Other characteristics of NCC-participating proteins include
a higher representation of aromatic residues (F, Y, W; p,
0.001 via unpaired two-tailed t-test; figure 4a), aliphatic residues
(I, V, L; p, 0.0001 via unpaired 2-tailed t-test; figure 4a) and
increased hydrophobicity (electronic supplementary material,
figure S5a)—attributes which explain the predicted high aggre-
gation propensity of NCC-participating proteins relative to
NCC-resistant proteins (figure 4d). Curiously, the intrinsic
disorder content (figure 4e) and themolecularweight (electronic
supplementary material, figure S5b) of NCC-participating
proteins were lower than those of NCC-resistant proteins.
These collective attributes further distinguish NCC from amy-
loidogenesis, which instead favours co-aggregation of large
hydrophobic proteins with high intrinsic disorder (figure 4f)
[34]. That diametrically opposed traits exist between NCC-
participating and NCC-resistant proteins shows that the same
physicochemical forces control these protein fates during necro-
sis. Indeed, our data show that whether a protein is retained or
released from necrotic cells is in part determined by its propen-
sity to undergo injury-induced aggregation. This conclusion
was independently supported by analysing the insoluble
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Only proteins quantified in at least two necrotic instances were considered. A fourth subset of 388 proteins randomly selected from the reviewed human nuclear/
cytoplasmic/mitochondrial proteome was also generated for control purposes (electronic supplementary material, table S1). The four subsets were used for physico-
chemical trait analysis. (a) Shown in green is the amino acid composition of NCC-participating proteins expressed relative to that of NCC-resistant proteins (arbitrarily
normalized to 1). Shown in grey is the predicted relative contribution of individual amino acids to amyloidogenic aggregation as defined in AGGRESCAN [33]
(arbitrarily normalized to 0). (b) Graph depicting a significant ( p , 0.0001) positive correlation between the relative cysteine content and the tendency for proteins
to undergo NCC (i.e. SILAC ratio) as determined by Pearson’s correlation analysis (where the black solid line represents the line of best fit and black dashed lines
indicate 95% confidence intervals). (c– e) Graphs comparing the degree of native disulfide bonding (c), the predicted aggregation propensity as determined by
AGGRESCAN [33] (d ) and the intrinsic disorder content (e) across the four protein subsets. For the box plots in (d,e), the centre line indicates the median,
box edges indicate the 25th/75th percentile and whiskers indicate the 10th/90th percentile. ****p, 0.0001 as determined by one-way ANOVA with Tukey’s correc-
tion. ( f ) Graph comparing the average molecular weight (kDa), hydrophobicity and % disorder for the NCC-participating, NCC-resistant and unchanged protein
subsets with that of amyloid interacting proteins identified in [34] (another protein subset from electronic supplementary material, table S1).
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mouse AT3 mammary adenocarcinoma cells; electronic
supplementary material, figure S6 and table S1).2.3. Identifying higher-order features of
nucleocytoplasmic coagulation
Many factors besides primary sequence affect protein
aggregation. Foremost among these factors is the concentration
dependency of protein aggregation. In line with this tenet,
NCC-participating proteins were found to be more abundant
than NCC-resistant proteins (figure 5a). Next, we performed
ontology enrichment analysis to gain a broader sense of what
molecular functions (figure 5b; electronic supplementary
material, table S2) and subcellular compartments (electronic
supplementary material, figure S7a and table S3) were affectedbyNCC. These analyses showed that NCCpreferentially affects
metabolic (e.g. GTPases), oxidoreductase (e.g. dehydrogenases,
periorodoxins), signalling (e.g. kinases) and proteostatic
enzymes (e.g. HSPs, translation factors), as well as nucleotide-
and nucleic acid-binding proteins ( p, 0.05; electronic
supplementary material, table S2). NCC was also found to
preferentially affect macromolecular complexes in the nucleus
(e.g. nuclear pore), cytoplasm (e.g. chaperonin, proteosome,
cytoskeleton) and mitochondria (electronic supplementary
material, figure S7a and table S3), subcellular compartments
with a constitutively redox-reduced state (p, 0.05; electronic
supplementary material, table S3). By comparison, distinct
molecular functions and subcellular compartments were
prevalent among NCC-resistant proteins (electronic supple-
mentary material, tables S2 and S3). Thus, numerous
energetic and homeostatic functions in the nucleus, cytoplasm
and mitochondria are directly affected by NCC.
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Figure 5. NCC preferentially affects abundant ancient proteins that perform essential cellular functions and exhibit reduced autoreactivity. (a– e) The same high-
confidence protein subsets and the randomly selected control subset from figure 4 were further analysed. (a) Graph comparing the abundance across the different
protein subsets. Black lines indicate the average abundance of each subset. ***p , 0.001 as determined by one-way ANOVA with Tukey’s correction. (b) Network
depicting the molecular functions that were significantly over-represented in the NCC-participating subset, relative to the complete human proteome. Nodes (circles)
represent different molecular function ontologies. Functionally related nodes are connected by edges (straight lines) and have been grouped using ClueGO [35], k 
0.4. The node size is proportional to the statistical significance of enrichment. The coloured pie segments that fill each node indicate the per cent of the ontology
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NCC causes aggregation of seemingly unrelated proteins (i.e.
the NCC-interactome has low connectivity; electronic sup-
plementary material, figure S7b) that participate in a high
number of protein–protein interactions (especially, homotypic
interactions; electronic supplementary material, figure S7b).
That NCC preferentially affects fundamental enzyme
complexes agrees well with the observation that NCC-partici-
pating proteins are evolutionarily more ancient than
NCC-resistant proteins (figure 5c). Altogether, our data
suggest that NCC preferentially shuts down a wide array of
ancient proteins with essential interactions and functions.
NCC is therefore likely to be a rudimentary response that ‘inac-
tivates’ necrotic cells.2.4. Putative role for nucleocytoplasmic coagulation in
attenuating autoimmunity
Maintaining tolerance after injury is a necessary and proble-
matic process, especially given that cell death can allowthe unwanted exposure/release of epitopes that would other-
wise be sequestered from the immune system. Indeed, cell
death is a potent trigger of inflammation, with autoimmune dis-
ease often preceded by injury [24–27]. Moreover, defective
or inadequate removal of dead cells underlies the onset of
many autoimmune disorders including system lupus
erythematosus [28]. Accordingly, we hypothesized that NCC,
by restricting the escape of constituents from necrotic cells and
bypromoting tolerogenic clearance [21], is a favourable response
that mitigates autoimmunity. To support this hypothesis, we
assessed the representation of known autoantigens (using a set
of 2079 autoantigens fromBackes et al. [36]) and found that auto-
antigens were far more prevalent among the NCC-resistant
subpopulation (figure 5d). Furthermore, the primary amino
acid composition of autoantigens closely mirrored that of
NCC-resistant proteins, with cysteines (p, 0.0001), aliphatic
residues (I, V, L; p, 0.0001) and aromatic residues (F, Y, W;
p, 0.0001) being under-represented, and charged residues
(D, E, K, R; p, 0.0001) being over-represented in autoantigens
(figure 5e). Collectively, this profile may allow autoantigens to
evade NCC and thereby promote their release into the
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add support to thehypothesis thatNCC is a favourable response
thatmaymitigate autoimmunity. Future studies shouldnow test
whethermutations that increase aprotein’s tendency to undergo
NCC also reduce its autoreactivity following necrosis—an
approach that holds great appeal for investigating the basis of
lupus and other injury-related autoimmune disorders.
2.5. Concluding remarks
A cascade of events that accounts for both our previous [10,12]
and current findings is where NCC relies upon membrane dis-
ruption during necrosis (either primary or secondary necrosis).
Membrane failure would cause a major loss of redox potential
and widespread oxidation, which in turn would preferen-
tially disulfide-crosslink abundant protein complexes within
otherwise redox-reduced compartments. Our prior studies
also suggest that initial misfolding events (e.g. linchpin residue
oxidation) that precede necrosis may be a prerequisite for NCC
[10,12]. We postulate that NCC represents a fail-safe switch that
ensures irreversible metabolic and proteostatic incompetency
during intense injury. The proteomic coverage of NCC is
muchwider than first thought, with a large number of essential
proteins and macromolecular structures entrapped by NCC,
thereby preventing their release into the extracellular space.
Entrapment by NCC, however, is a selective process because a
small proportion of the proteome (including FUS) avoids
NCC and is therefore selectively released into the extracellular
milieu upon necrosis. As the release of intracellular molecules
upon necrosis is deleterious, NCC is likely to be a beneficial
response that helps multicellular organisms restore tissue
homeostasis after injury. This supposition is somewhat coun-
terintuitive given that amyloidogenic protein aggregation
promotes neurodegenerative diseases. However, based on the
similar albeit distinct physicochemical signatures of NCC and
amyloidogenesis,wehypothesize thatNCCmaybean ‘offshoot
pathway’ that prevents deleterious amyloid formation in necro-
tic cells (electronic supplementary material, figure S4). Such
interrelations between amyloidogenic aggregation and NCC
should now be assessed. Beyond this, it is intriguing that fea-
tures such as cysteine content, hydrophobicity, intrinsic
disorder and abundance dictate whether a protein is retained
or released from necrotic cells. This understanding broadens
the biology of protein aggregation and indicates that reduction-
ist biochemical approaches used in the field of protein
misfolding may also be used to investigate the immunogenic
and inflammatory nature of necrosis.3. Material and methods
3.1. Materials
Reagents were from Sigma unless otherwise indicated. Soluble
Fas ligand (SuperFasLigand) was from Enzo Life Science.
NuPAGE Novex Bis-Tris Mini gel (4–12%), NuPAGE MOPS
SDS Running buffer, RPMI media, penicillin and streptomycin,
dialysedandnon-dialysed fetal calf serum (FCS), TO-PRO-3 and
7-AADwere from Life Technologies. Immobilon-FL polyvinyli-
dene difluoride (PVDF) membrane and Protein G Plus/Protein
A agarose (50% suspension) beads were from Merck Millipore.
Cell culture SILAC reagents were from Cambridge Isotope
Laboratories. InstantBlue protein stain was from CBS Scientific.
Sequence Grade Modified Trypsin (34 V511A), CytoTox96non-radioactive cytotoxicity (LDH) and CellTitre96 aqueous
non-radioactive cell proliferation (MTS) assays were from
Promega. Odyssey Blocking Buffer and IRdye secondary anti-
bodies (800CW donkey anti-mouse IgG, 680LT donkey anti-
mouse IgG, 800CW donkey anti-rabbit IgG, 680LT donkey
anti-rabbit IgG, 800CW donkey anti-goat IgG and 680LT
donkey anti-goat IgG) were from LI-COR Biosciences. Primary
antibodies were from Santa Cruz Biotechnology unless
stipulated otherwise: anti-RIPK1 (BD Biosciences, #610458),
anti-LC3 (MBT International, #PM036), mouse anti-HSP90b
(Abcam, #ab82522), rabbit anti-a-tubulin (Merck Millipore,
#04–1117), mouse anti-b-tubulin (Sigma,#T0198), goat
anti-b-actin (#sc-1616), goat anti-PRX1 (#sc-7381), rabbit anti-
Cyclophilin A (Abcam, #ab41684), goat anti-PGK1 (#sc-17943),
mouse anti-3PDGH (#sc-100317), rabbit anti-EF1 (#sc-28578),
goat anti-IMPDH2 (Abnova, #PAB19702), mouse anti-TCP1b
(#sc-373769), mouse anti-MCM7 (#sc-56324), goat anti-EF2
(#sc-13004), mouse anti-LRP130 (#sc-166178), mouse anti-
GAPDH (Merck Millipore, #MAB374), mouse anti-FUS/TLS
(#sc-373698), mouse anti-SSRP1 (#sc-56781), mouse anti-Skip
(#sc-136546), rabbit anti-ribosomal protein S19 (#sc-134779),
mouse anti-Cdc5 L (#sc-81220), mouse anti-C23 (#sc-8031) and
rabbit anti-GAPDH (#sc-25778).
3.2. Cell culture
Jurkat andU937 cells weremaintained as non-adherent cultures
in RPMI supplemented with 10%(v/v) heat-inactivated FCS,
2 mM L-glutamine, 50 U ml21 penicillin and 50 U ml21 strepto-
mycin (P/S) under humidified 5% CO2. AT3 cells were
maintained as an adherent culture in DMEM supplemented
with 10%(v/v) heat-inactivated FCS, 2 mM L-glutamine,
50 U ml21 penicillin and 50 U ml21 streptomycin (P/S) under
humidified 5% CO2. For injury induction, cells were resuspend
cells in RPMI/DMEM supplemented with 1%(v/v) heat-
inactivated FCS, P/S and L-glutamine. Cells were then seeded
at 0.15  106 live cells per well (for Jurkat and AT3 cells) or
0.1 106 live cells per well (for U937 cells) in 24-well plates
and allowed to equilibrate for 1 h. Injury-causing treatments or
an equivalent amount of DMSO (as the vehicle) were then
added to their final concentrations: 300 nM staurosporine,
25 mg ml21 etoposide (for Jurkat cells) or 6 mg ml21 etoposide
(for U937 cells), 40 ng ml21 soluble Fas ligand and 500 nM dox-
orubicin. Injury was assessed 3–24 h later (as stipulated in the
corresponding figure legend). For stable Lysine isotope incor-
poration, cells were maintained for more than 10 passages in
Lysine- and Arginine-free RPMI/DMEM media supplemen-
ted with 10% dialysed FCS, P/S, L-glutamine, 0.1 g l21 of
unlabelled L-Arginine : HCl and either 0.1 g l21 of unlabelled
L-Lysine : 2HCl or 0.1 g l21 of L-Lysine : 2HCl (U-13C6, 99%).
3.3. Cell injury assays (LDH, MTS and trypan blue assays)
LDH and MTS assay kits were from Promega and were
performed according to the manufacturer’s instructions.
Trypan blue positivity was determined using the TC-10
Automated Cell counter (Bio-Rad) according to the
manufacturer’s instructions.
3.4. Flow cytometry
Jurkat and U937 cells (seeded and treated as in §3.2) were
incubated for the indicated time period. Cells were then
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conjugated-Annexin V and 250 mM TO-PRO-3 or 7-AAD
and subject to flow cytometry (BD Accuri C6 Plus flow cyt-
ometer). Data were analysed off-line using FLOWJO v. 10.1r5.
3.5. Cell homogenization and fractionation
Cells were collected, washed in PBS, pelleted and resuspended
in ice-cold lysis buffer (PBS þ 1% Triton X-100 þ 1 complete
EDTA-free protease cocktail (Roche) þ 1 PhosSTOP phospha-
tase inhibitor cocktail (Roche) þ 10 mM chloroacetamide).
Chloroacetamide was added to the lysis buffer to prevent
inadvertent disulfide bond formation during/after cell
homogenization and subsequent fractionation. Note, chloro-
acetamide was chosen over iodoacetamide as it reacts more
specifically with cysteine thiols [42]. Homogenates were tritu-
rated and then stored at 2808C until further fractionation was
necessary; 1 ml of lysis buffer was used per 0.6  106 cells
(for Jurkat cells) or per 0.4  106 cells (for U937 cells). To extract
the soluble and insoluble fractions, 1 ml of homogenate was
centrifuged (48C, 16 000g, 30 min). The supernatant was kept
as the ‘Triton-soluble fraction’ and the pellet was washed in
1 ml of PBS þ 1% Triton X-100 and incubated for 1 h with
gentle mixing at 258C in 60 ml of 62.5 mM Tris–HCl (pH 6.8),
2% SDS, 5% glycerol with or without 0.1 M DTT. Finally,
the sample was centrifuged (258C, 16 000g, 30 min) and the
supernatant kept as the ‘Triton-insoluble fraction’.
3.6. SDS-PAGE
3.6.1. SDS-PAGE for immunoblotting
Samples (50 ml of Triton-soluble fraction and the entire
Triton-insoluble fraction) were boiled in 2% SDS-loading
buffer with or without dithiothreitol, subjected to SDS-
PAGE, and transferred onto PVDF membranes. Membranes
were probed with the appropriate IR-dye-conjugated second-
ary antibody (LI-COR) and signals revealed with an Odyssey
scanner (LI-COR).
3.6.2. SDS-PAGE for tryptic digestion
Samples were boiled in 2% SDS-loading buffer with dithio-
threitol and subjected to SDS-PAGE using a NuPAGE
Novex Bis-Tris Mini gel (4–12%) with NuPAGE MOPS
SDS-Running buffer supplemented with 1 NuPAGE antiox-
idant (Life Technologies). After electrophoresis, the gel was
stained with InstantBlue protein stain and cut into approxi-
mately 2  6 mm slices then each slice further cut into
1 mm2 pieces. Gel pieces were subjected to in-gel trypsin
digestion as in [43].
3.7. Mass spectrometry
Liquid chromatography tandem mass spectrometry was
performed as in [44] with minor modifications. Extracted
peptides were analysed by Q-Exactive Orbitrap mass spec-
trometer (Thermo Scientific) coupled online with an RSLC
nano-HPLC (Ultimate 3000, Thermo Scientific). Samples
were injected onto a Thermo RSLC pepmap100, 75um id,
100 angstrom pore size, 50 cm reversed phase nano column
with buffer A (2.5% acetonitrile, 0.1% formic acid) at a flow
rate of 300 nl min21. The peptides were eluted over a40-min gradient to 40% buffer B (80% acetonitrile 0.1%,
formic acid). The eluate was nebulized and ionized using
the Thermo nano electrospray source coated silica emitter
with a capillary voltage of 1700 V. Peptides were selected
for MS/MS analysis using XCALIBUR software (Thermo
Fisher) in Full MS/dd-MS2 (TopN) mode with the following
parameter settings: TopN 10, MSMS AGC target 1e5, 60 ms
Max IT, NCE 27 and 2 m/z isolation window. Dynamic
exclusion was set to 20 s.
MS data were analysed with MAXQUANT [45] software
v. 1.3.0.5. Search parameters included: specific digestion with
trypsin with up to two missed cleavages, þ6 Lysine was set
as label, protein N-terminal acetylation and methionine oxi-
dation were set as variable modifications while cysteine
alkylationwas set as fixedmodification. The searches were per-
formed against UniProt human protein sequences (March 2013
version). The remaining search parameters were default set-
tings. The search was then imported into PERSEUS software
[45] for collation (electronic supplementary material, table S1)
and for further annotation. Note that the gating of SILAC
ratios for analysis is explained in the respective figure legends.
These gating strategies were based on the recommendations of
Zhang & Neubert [31], with more than 95% of the identified
proteins having a ratio that fell within the ‘unchanged’
intermediary gate in the corresponding uninjured cell samples.
3.8. Immunoprecipitation
Jurkat cellswere treated for 24 h and the conditionedmedia col-
lected. Fifteen microlitres of Protein-G/-A beads (as a 50%
slurry) was added to 1.3 ml of conditioned media and the mix-
ture gently rotated (30 min, 48C). The beads were centrifuged
(2 min, 3000g) and discarded; 20 ml of Protein-G/-A beads þ
1 mg of anti-MCM7 antibody was added to the supernatant
and the mixture gently rotated (3 h, 48C). The beads were cen-
trifuged (2 min, 3000g) and kept as the ‘MCM7 pulldown’
material; 20 ml of Protein-G/-A beads þ 1 mg of anti-FUS anti-
body was added to the supernatant and the mixture gently
rotated (3 h, 48C). The beads were centrifuged (2 min, 3000g)
and kept as the ‘FUS pulldown’ material. The beads were
boiled for 10 min in 35 ml of SDS-loading buffer with dithio-
threitol and the supernatants subjected to SDS-PAGE/
immunoblot analysis. Quantitation of the immunoprecipitation
signal was performed using IMAGEQUANT v. 5.2 software (Mol-
ecular Dynamics) and expressed relative to the total amount
of FUS present in the Triton-soluble lysate from uninjured
Jurkat cells.
3.9. Immunofluorescence
3.9.1. Immunofluorescence for maleimide co-staining
Twenty-four hour-treated Jurkat cells were fixed in 2% parafor-
maldehydewith 40 mMchloroacetamide (48C, 40 min, in dark).
Cells were immobilized onto Superfrost slides (Tharmac
Cellspin II, 320 g, 5 min) and incubated in 4% paraformalde-
hyde with 40 mM chloroacetamide (5 min, in dark). Cells
were incubated in TBS-T (100 mM Tris–HCl pH 8.0 þ
150 mMNaCl þ 0.05%Tween20)with 40 mMchloroacetamide
(20 min in dark). Cells were washed then incubated in TBS-T
with 20 mM TCEP (20 min in dark). Cells were washed then
incubated in TBS-Twith 50 nMAlexaFluor488-conjugatedmal-
eimide (20 min in dark). Cells were washed then incubated in
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(overnight, 48C in dark). Cells were washed then incubated in
TBS-Twith 5% FCS and 1 : 1000 dilution of secondary antibody
(AlexaFluor 568-conjugated donkey anti-mouse/goat IgG and
CF647-conjugated donkey anti-rabbit IgG (Biotium), 2 h, in
dark). Cells were stained in 10 mg l21 Hoechst 33342, washed
in TBS-T then mounted in Fluorescent Mounting Media
(DAKO). Cells were imaged on a Nikon A1r-si resonant scan-
ning confocal system (microscope: Nikon Ti, Tokyo, Japan;
objective: Apo LWD, 40 magnification, 1.15 numerical
aperture, water immersion; sequential excitation: 405, 488, 561
and 638 nm lasers; emission: 450/50, 525/50, 595/50 and
700/75 nm filters; acquisition software: NIS Elements
Advanced Research, Tokyo, Japan). Images were processed
using IMAGEJ v. 1.50d software (National Institute of Health).
3.9.2. Immunofluorescence for super-resolution microscopy
Jurkat cells were immunostained as above but without
Hoechst 33 342 counterstaining. Cells were mounted in
ProLong Diamond Antifade Mountant (Life Technologies)
using high precision #1.5 glass coverslips (0.17+0.01 mm;
Menzel-Gla¨ser). Samples were imaged by Stimulated
Emission Depletion microscopy using a Leica TCS SP8
STED 3 platform (microscope: DMi8 inverted, objective:
HC PL APO CS2 100/1.40 oil, excitation: tunable pulsed
white light laser, depletion: 775 nm and 592 nm depletion
lasers, detection: sequential HyD detectors; software: LAS
AF X). Images were processed using IMAGEJ v. 1.50d
software (National Institute of Health).
3.10. Protein property analysis
3.10.1. Protein sequence analysis
Canonical FASTA sequences for the different protein subsets
(electronic supplementary material, table S1) were retrieved
from UniProt and entered into the Sequence Manipulation
Suite [46] to determine amino acid content, hydrophobicity
and molecular weight.
3.10.2. Protein aggregation prediction
Canonical FASTA sequences for the different protein subsets
(electronic supplementary material, table S1) were retrieved
from UniProt and uploaded to the AGGRESCAN [33] site
to ascertain the predicted aggregation propensity. Note,
only proteins with less than 1000 residues were analysed.
AGGRESCAN provides the relative aggregation propensity
of amino acids within both the central hydrophobic cluster
of b-amyloid and within the context of a larger full-length
soluble polypeptide [33]. AGGRESCAN’s aggregation pro-
pensities are derived from in vivo experimental data [33].
Similar analyses (with similar results) were performed
using the FoldAmyloid [39] and Zyggregator [40] databases
(not shown).
3.10.3. Intrinsic disorder content analysis
UniProt IDs (electronic supplementary material, table S1)
were used to query the MobiDB 2.0 database [47]. The per-
centage of each protein in disorder (either from curated
data or from consensus predicted data when no curated
data existed) irrespective of segment was determined.3.10.4. Autoantigen analysis
UniProt IDs (electronic supplementary material, table S1)
were cross-referenced against the full set of autoantigens
from Backes et al. [36].
3.10.5. Protein abundance analysis
The different protein subsets (electronic supplementary
material, table S1) were uploaded to the PaxDB [48] site
and their organismal abundance was retrieved from the
Human PaxDB integrated dataset.
3.10.6. Protein age analysis
Protein age was determined using the ProteinHistorian [49]
website, whereby protein subsets were individually analysed
via the swisspfam-PTHR7_youngest database and the Dollo
parsimony reconstruction algorithm.
3.10.7. Native disulfide bond analysis
Annotations from the UniProt [50] database were used to
determine the number and location of native disulfide
bonds for each protein of interest.
3.10.8. Ontology enrichment analysis
CYTOSCAPE v. 3.2.0 and the ClueGO v. 2.2.5 and CluePedia
v. 1.2.5 plug-ins was used to perform ontology enrichment
analysis as in [35]. Molecular function enrichment analysis
was performed within GO term levels 3–5. Cellular compart-
ment enrichment analysis was performed within GO term
levels 4–10.
3.10.9. Protein–protein interaction analysis
The high-confidence NCC-participating protein subset was
entered into the Mentha [51] interactome database. All
human interacting proteins were extracted and visualized
as a network using Cytoscape. Duplicate interactions were
removed and the network rendered directionless. The top-
ology and characteristics of the resultant network was
analysed using the Network Analyser plug-in [52].
3.11. Statistical analyses
All results are based on three independent experiments
unless stipulated otherwise. Analyses were performed with
GraphPad PRISM 6 with p, 0.05 considered statistically sig-
nificant. The analysis employed for each cohort is stated in
the respective figure legend.
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